Monte Rosa Therapeutics, Inc.
GLUE
$18.15
-$0.53-2.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 3.54% | -70.36% | -120.26% | -126.22% | 248.92% |
| Total Depreciation and Amortization | -3.22% | 1.06% | 0.63% | 3.55% | 1.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.06% | 14.17% | -8.58% | -1.90% | 11.47% |
| Change in Net Operating Assets | 104.19% | -102.77% | 523.30% | 70.90% | -189.95% |
| Cash from Operations | 13.12% | -142.83% | 389.25% | 23.68% | -135.29% |
| Capital Expenditure | -143.55% | -17.82% | 61.59% | -6.81% | -767.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -303.01% | -265.77% | 43.56% | 127.39% | -221.17% |
| Cash from Investing | -301.13% | -270.61% | 50.60% | 125.27% | -224.41% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,065.81% | 8,515.23% | -4.66% | 2,507.14% | -97.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5,834.73% | -- | -- | -- | -- |
| Cash from Financing | 1,008.34% | 8,412.64% | -4.66% | 2,507.14% | -97.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 138.20% | -156.48% | 1,638.19% | 93.80% | -247.72% |